IntegenX Licenses Caliper’s Microfluidics Patent Portfolio to Build Apollo 200 RapidHIT™ DNA Profiling System

PR Newswire
– Agreement Enables Commercial Launch into Forensics Markets –
PLEASANTON, Calif. and HOPKINTON, Mass., Feb. 22, 2011 /PRNewswire/ — IntegenX Inc. (a privately held corporation) and Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced a license agreement providing IntegenX access to Caliper’s microfluidics patent portfolio. IntegenX will leverage its proprietary MOVe™ microvalve technology and Caliper’s microfluidic intellectual patent estate to accelerate commercialization of its Apollo 200 RapidHIT™ DNA Profiling System for human identification.